Publications by authors named "T Engler"
Breast cancer (BC) is a heterogeneous disease, traditionally classified by hormone receptor and HER2 (human epidermal growth factor receptor 2) status. HER2-low, characterized by low HER2 expression without gene amplification, recently gained attention. While new therapies are promising, its clinical significance remains unclear.
View Article and Find Full Text PDFCisplatin is used to treat a variety of malignancies, including testicular germ cell tumours (TGCTs). Although cisplatin-based chemotherapy yields high response rates, a subset of patients develop cisplatin resistance, limiting treatment options and worsening prognosis. Therefore, there is a high clinical need for new therapeutic strategies targeting cisplatin-resistant TGCTs.
View Article and Find Full Text PDFArticle Synopsis
- Ovarian cancer often leads to muscle loss, malnutrition, and fatigue, adversely affecting patients' quality of life, especially during first-line chemotherapy.
- A new study aims to assess an app-based exercise and nutrition program's effectiveness over six months compared to standard care, with physical performance measured by the 6-Minute Walk Test as the main focus.
- The study will involve a multicenter trial with a minimum of 182 participants, all diagnosed with advanced ovarian cancer, and assess various health and nutrition indicators alongside physical performance improvements.
Impact of obesity on pathological complete remission in early stage breast cancer patients after neoadjuvant chemotherapy: a retrospective study from a German University breast center.
Arch Gynecol Obstet
February 2025
Purpose: Breast cancer is a primary cause of cancer-related death among women worldwide. Neoadjuvant chemotherapy (NACT) is a cornerstone treatment for locally advanced, non-metastatic breast cancer. Achieving pathological complete response (pCR) is often used as a surrogate marker for long-term outcomes.
View Article and Find Full Text PDFIntroduction: The third-generation antibody-drug conjugates (ADC), trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), recently obtained approval for metastatic breast cancer treatment across various subtypes and therapeutic contexts.
Materials And Methods: This retrospective, multicentric study evaluated real-world tolerability, feasibility and efficacy in a pre-treated, real-world cohort at three major German breast cancer centers.
Results: 125 patients treated with T-DXd or SG from November 2020 to June 2023 were included (T-DXd: 77 patients; SG: 48 patients).